177 related articles for article (PubMed ID: 37376642)
1. Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus.
Wagner N; Shayakhmetov DM; Stewart PL
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376642
[TBL] [Abstract][Full Text] [Related]
2. Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo.
Doszpoly A; de la Cuesta F; Lopez-Gordo E; Bénézech C; Nicklin SA; Baker AH
Viruses; 2019 Jul; 11(7):. PubMed ID: 31284434
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Modeling of Complement C4 Mediated Neutralization of Adenovirus.
Emerson CC; Stewart PL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33467558
[TBL] [Abstract][Full Text] [Related]
4. Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction
Lopez-Gordo E; Doszpoly A; Duffy MR; Coughlan L; Bradshaw AC; White KM; Denby L; Nicklin SA; Baker AH
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381574
[TBL] [Abstract][Full Text] [Related]
5. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.
Ma J; Duffy MR; Deng L; Dakin RS; Uil T; Custers J; Kelly SM; McVey JH; Nicklin SA; Baker AH
PLoS Pathog; 2015 Feb; 11(2):e1004673. PubMed ID: 25658827
[TBL] [Abstract][Full Text] [Related]
6. The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery.
Lopez-Gordo E; Denby L; Nicklin SA; Baker AH
Expert Opin Drug Deliv; 2014 Nov; 11(11):1795-813. PubMed ID: 25036189
[TBL] [Abstract][Full Text] [Related]
7. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.
Xu Z; Qiu Q; Tian J; Smith JS; Conenello GM; Morita T; Byrnes AP
Nat Med; 2013 Apr; 19(4):452-7. PubMed ID: 23524342
[TBL] [Abstract][Full Text] [Related]
8. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
[TBL] [Abstract][Full Text] [Related]
9. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
Krutzke L; Prill JM; Engler T; Schmidt CQ; Xu Z; Byrnes AP; Simmet T; Kreppel F
J Control Release; 2016 Aug; 235():379-392. PubMed ID: 27302248
[TBL] [Abstract][Full Text] [Related]
10. Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.
Sumarheni S; Hong SS; Josserand V; Coll JL; Boulanger P; Schoehn G; Fender P
Hum Gene Ther; 2014 Apr; 25(4):339-49. PubMed ID: 24512117
[TBL] [Abstract][Full Text] [Related]
11. Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.
Madisch I; Hofmayer S; Moritz C; Grintzalis A; Hainmueller J; Pring-Akerblom P; Heim A
J Virol; 2007 Aug; 81(15):8270-81. PubMed ID: 17522221
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
Beebe DP; Cooper NR
J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
[TBL] [Abstract][Full Text] [Related]
14. Complement C4 Prevents Viral Infection through Capsid Inactivation.
Bottermann M; Foss S; Caddy SL; Clift D; van Tienen LM; Vaysburd M; Cruickshank J; O'Connell K; Clark J; Mayes K; Higginson K; Lode HE; McAdam MB; Sandlie I; Andersen JT; James LC
Cell Host Microbe; 2019 Apr; 25(4):617-629.e7. PubMed ID: 30926239
[TBL] [Abstract][Full Text] [Related]
15. Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum.
Harmon AW; Moitra R; Xu Z; Byrnes AP
PLoS One; 2018; 13(2):e0192353. PubMed ID: 29401488
[TBL] [Abstract][Full Text] [Related]
16. The relevance of coagulation factor X protection of adenoviruses in human sera.
Duffy MR; Doszpoly A; Turner G; Nicklin SA; Baker AH
Gene Ther; 2016 Jul; 23(7):592-6. PubMed ID: 27014840
[TBL] [Abstract][Full Text] [Related]
17. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.
Corjon S; Gonzalez G; Henning P; Grichine A; Lindholm L; Boulanger P; Fender P; Hong SS
PLoS One; 2011; 6(5):e18205. PubMed ID: 21637339
[TBL] [Abstract][Full Text] [Related]
18. An intrinsically disordered region of the adenovirus capsid is implicated in neutralization by human alpha defensin 5.
Flatt JW; Kim R; Smith JG; Nemerow GR; Stewart PL
PLoS One; 2013; 8(4):e61571. PubMed ID: 23620768
[TBL] [Abstract][Full Text] [Related]
19. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization.
Smith JG; Silvestry M; Lindert S; Lu W; Nemerow GR; Stewart PL
PLoS Pathog; 2010 Jun; 6(6):e1000959. PubMed ID: 20585634
[TBL] [Abstract][Full Text] [Related]
20. Identification of adenovirus neutralizing antigens using capsid chimeric viruses.
Liu T; Fan Y; Li X; Gu S; Zhou Z; Xu D; Qiu S; Li C; Zhou R; Tian X
Virus Res; 2018 Sep; 256():100-106. PubMed ID: 30096411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
